These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 21572644)

  • 1. Adverse drug reaction profile of nanoparticle versus conventional formulation of paclitaxel: An observational study.
    Brahmachari B; Hazra A; Majumdar A
    Indian J Pharmacol; 2011 Apr; 43(2):126-30. PubMed ID: 21572644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and economic implications of the use of nanoparticle paclitaxel (Nanoxel) in India.
    Ranade AA; Joshi DA; Phadke GK; Patil PP; Kasbekar RB; Apte TG; Dasare RR; Mengde SD; Parikh PM; Bhattacharyya GS; Lopes GL
    Ann Oncol; 2013 Sep; 24 Suppl 5():v6-12. PubMed ID: 23975704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficiency and mechanism of intracellular paclitaxel delivery by novel nanopolymer-based tumor-targeted delivery system, Nanoxel(TM).
    Madaan A; Singh P; Awasthi A; Verma R; Singh AT; Jaggi M; Mishra SK; Kulkarni S; Kulkarni H
    Clin Transl Oncol; 2013 Jan; 15(1):26-32. PubMed ID: 22855169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) formulation and paclitaxel in polyethoxylated castor oil: a randomized, two-period crossover study in patients with advanced cancer.
    Slingerland M; Guchelaar HJ; Rosing H; Scheulen ME; van Warmerdam LJ; Beijnen JH; Gelderblom H
    Clin Ther; 2013 Dec; 35(12):1946-54. PubMed ID: 24290734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of docetaxel-loaded intravenous formulation, Nanoxel-PM™ using polymer-based delivery system.
    Lee SW; Yun MH; Jeong SW; In CH; Kim JY; Seo MH; Pai CM; Kim SO
    J Control Release; 2011 Oct; 155(2):262-71. PubMed ID: 21704664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
    Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse drug reactions due to cancer chemotherapy in a tertiary care teaching hospital.
    Wahlang JB; Laishram PD; Brahma DK; Sarkar C; Lahon J; Nongkynrih BS
    Ther Adv Drug Saf; 2017 Feb; 8(2):61-66. PubMed ID: 28255433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy.
    Kang YK; Ryu MH; Park SH; Kim JG; Kim JW; Cho SH; Park YI; Park SR; Rha SY; Kang MJ; Cho JY; Kang SY; Roh SY; Ryoo BY; Nam BH; Jo YW; Yoon KE; Oh SC
    Ann Oncol; 2018 May; 29(5):1220-1226. PubMed ID: 29438463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.
    Ibrahim NK; Desai N; Legha S; Soon-Shiong P; Theriault RL; Rivera E; Esmaeli B; Ring SE; Bedikian A; Hortobagyi GN; Ellerhorst JA
    Clin Cancer Res; 2002 May; 8(5):1038-44. PubMed ID: 12006516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse event profiles of solvent-based and nanoparticle albumin-bound paclitaxel formulations using the Food and Drug Administration Adverse Event Reporting System.
    Naganuma M; Tahara K; Hasegawa S; Fukuda A; Sasaoka S; Hatahira H; Motooka Y; Nakao S; Mukai R; Hirade K; Yoshimura T; Kato T; Takeuchi H; Nakamura M
    SAGE Open Med; 2019; 7():2050312119836011. PubMed ID: 30886713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter phase II randomized study of Cremophor-free polymeric nanoparticle formulation of paclitaxel in women with locally advanced and/or metastatic breast cancer after failure of anthracycline.
    Ranade AA; Bapsy PP; Nag S; Raghunadharao D; Raina V; Advani SH; Patil S; Maru A; Gangadharan VP; Goswami C; Sekhon JS; Sambasivaiah K; Parikh P; Bakshi A; Mohapatra R
    Asia Pac J Clin Oncol; 2013 Jun; 9(2):176-81. PubMed ID: 23176568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer.
    Northfelt DW; Allred JB; Liu H; Hobday TJ; Rodacker MW; Lyss AP; Fitch TR; Perez EA;
    Am J Clin Oncol; 2014 Apr; 37(2):167-71. PubMed ID: 23211220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of paclitaxel (BMS-181339) intravenously infused over 3 hours for advanced or metastatic breast cancer in Japan. BMS-181339 Breast Cancer Study Group.
    Ito Y; Horikoshi N; Watanabe T; Sasaki Y; Tominaga T; Okawa T; Tabei T; Kuraishi Y; Tamura K; Abe R; Kitajima M; Yamaguchi S; Kobayashi T; Koyama H; Orita K; Takashima S; Nomura Y; Ogawa M
    Invest New Drugs; 1998; 16(2):183-90. PubMed ID: 9848584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative
    Do VQ; Park KH; Park JM; Lee MY
    Toxicol Res; 2019 Apr; 35(2):201-207. PubMed ID: 31015902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.
    Gianni L; Munzone E; Capri G; Villani F; Spreafico C; Tarenzi E; Fulfaro F; Caraceni A; Martini C; Laffranchi A
    J Natl Cancer Inst; 1995 Aug; 87(15):1169-75. PubMed ID: 7674322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicity profile of Doxorubicin-Cyclophosphamide and Doxorubicin-Cyclophosphamide followed by Paclitaxel regimen and its associated factors among women with breast cancer in Ethiopia: A prospective cohort study.
    Gadisa DA; Assefa M; Wang SH; Yimer G
    J Oncol Pharm Pract; 2020 Dec; 26(8):1912-1920. PubMed ID: 32122234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system for paclitaxel.
    Mita AC; Olszanski AJ; Walovitch RC; Perez RP; MacKay K; Tuck DP; Simmons C; Hammond S; Mita MM; Beeram M; Stone AJ; Rowinsky EK; Lewis LD
    Clin Cancer Res; 2007 Jun; 13(11):3293-301. PubMed ID: 17545535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the relation between patient characteristics and the state of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer receiving paclitaxel and carboplatin.
    Furukawa N; Akasaka J; Shigemitsu A; Sasaki Y; Nagai A; Kawaguchi R; Kobayashi H
    Arch Gynecol Obstet; 2014 Apr; 289(4):859-64. PubMed ID: 24185939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.
    Shitara K; Takashima A; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Makari Y; Amagai K; Ueda S; Yoshida K; Shimodaira H; Nishina T; Tsuda M; Kurokawa Y; Tamura T; Sasaki Y; Morita S; Koizumi W
    Lancet Gastroenterol Hepatol; 2017 Apr; 2(4):277-287. PubMed ID: 28404157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy.
    Parinyanitikul N; Tanpipattanakul W; Poovorawan N; Rattananupong T; Laoitthi P; Sithidetphaiboon P; Thanasanvimon S; Sriuranpong V
    Support Care Cancer; 2018 Jul; 26(7):2471-2477. PubMed ID: 29435713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.